Is the drug name tucatinib/tucatinib tucatinib?

Tucatinib is a kinase inhibitor used in combination therapy for HER2-positive breast cancer and RAS wild-type HER2-positive colorectal cancer. The chemical name is (N4-([1,2,4]triazolo[1,5-a]pyridine-7-oxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrazol-2-yl)quinazoline-4,6-diamine. The molecular formula is C26H24N8O2, and the molecular weight is 480.52 g/mol. Tucatinib is availableas 50 mg and 150 mg oral film-coated tablets. Its names include tucatinib, tucatinib, tucatinib, etc., and its trade name is TUKYSA.

Tucatinib is indicated for use in combination with trastuzumab and capecitabine to treat adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-H-based therapies in the metastatic setting. ER2; or in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Tucatinib containstucatinib, a HER2 tyrosine kinase inhibitor. It works by inhibiting the growth of HER2-expressing tumors. The combination of tucatinib and trastuzumab showed increased antitumor activity compared with each drug alone. Tucatinib tablets are administered orally twice daily. Common adverse reactions include diarrhea, palmoplantar red blood cell paresthesias, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, rash, fatigue, abdominal pain, infusion-related reactions, and pyrexia.